Cargando…

The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management

Liquid biopsy (LB) has boosted a remarkable change in the management of cancer patients by contributing to tumour genomic profiling. Plasma circulating cell-free tumour DNA (ctDNA) is the most widely searched tumour-related element for clinical application. Specifically, for patients with lung cance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fernandes, Maria Gabriela O., Cruz-Martins, Natália, Machado, José Carlos, Costa, José Luís, Hespanhol, Venceslau
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8680243/ https://www.ncbi.nlm.nih.gov/pubmed/34915883 http://dx.doi.org/10.1186/s12935-021-02382-0

Ejemplares similares

Clinical Application of Next-Generation Sequencing of Plasma Cell-Free DNA for Genotyping Untreated Advanced Non-Small Cell Lung Cancer
por: Fernandes, Maria Gabriela O., et al.
Publicado: (2021)

Liquid Biopsy for Disease Monitoring in Non-Small Cell Lung Cancer: The Link between Biology and the Clinic
por: Fernandes, Maria Gabriela O., et al.
Publicado: (2021)

Resistance Profile of Osimertinib in Pre-treated Patients With EGFR T790M-Mutated Non-small Cell Lung Cancer
por: Fernandes, Maria Gabriela O., et al.
Publicado: (2021)

Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer
por: Kapeleris, Joanna, et al.
Publicado: (2022)

Targeted Gene Next-Generation Sequencing Panel in Patients with Advanced Lung Adenocarcinoma: Paving the Way for Clinical Implementation
por: Fernandes, Maria Gabriela O., et al.
Publicado: (2019)

Management of Coronavirus Disease 2019 Patients With Lung Cancer: Experience From a Thoracic Oncology Center
por: Coelho, David Barros, et al.
Publicado: (2021)

The Role of Liquid Biopsy in Early Diagnosis of Lung Cancer
por: Freitas, Cláudia, et al.
Publicado: (2021)

Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design
por: Kejík, Zdeněk, et al.
Publicado: (2021)

The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC
por: Nygaard, A D, et al.
Publicado: (2014)

The Impact of Polymorphic Variations in the 5p15, 6p12, 6p21 and 15q25 Loci on the Risk and Prognosis of Portuguese Patients with Non-Small Cell Lung Cancer
por: de Mello, Ramon Andrade, et al.
Publicado: (2013)

Chronic Bacterial Infection Prevalence, Risk Factors, and Characteristics: A Bronchiectasis Population-Based Prospective Study
por: Amorim, Adelina, et al.
Publicado: (2019)

Circulating Cell-Free Tumour DNA in the Management of Cancer
por: Francis, Glenn, et al.
Publicado: (2015)

The role of genetic polymorphisms at the chromosomes 5p15, 6p12, 6p21 and 15q25 in non-small-cell lung cancer prognosis: a Portuguese prospective study
por: de Mello, Ramon A, et al.
Publicado: (2013)

Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours
por: Sefrioui, David, et al.
Publicado: (2017)

Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non‐small‐cell lung cancer treated with pembrolizumab
por: Mondelo‐Macía, Patricia, et al.
Publicado: (2021)

Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update
por: Kapeleris, Joanna, et al.
Publicado: (2022)

Chemotherapy with cisplatin and vinorelbine for elderly patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC)
por: Pereira, José Rodrigues, et al.
Publicado: (2004)

EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer
por: Foy, Victoria, et al.
Publicado: (2021)

Circulating Tumour Cells: Detection and Application in Advanced Non-Small Cell Lung Cancer
por: Andrikou, Kalliopi, et al.
Publicado: (2023)

Identifying relationships between imaging phenotypes and lung cancer-related mutation status: EGFR and KRAS
por: Pinheiro, Gil, et al.
Publicado: (2020)

Significant diagnostic value of circulating tumour cells in colorectal cancer
por: Yu, Haijiao, et al.
Publicado: (2020)

Circulating tumour cells in breast cancer
por: Krawczyk, Natalia, et al.
Publicado: (2013)

Biosensors for the Detection of Circulating Tumour Cells
por: Costa, Clotilde, et al.
Publicado: (2014)

Clinical predictive value of naïve and memory T cells in advanced NSCLC
por: Zhang, Guan, et al.
Publicado: (2022)

Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis
por: Luo, Jie, et al.
Publicado: (2014)

Circulating Cell-Free Tumour DNA for Early Detection of Pancreatic Cancer
por: Jaworski, Jedrzej J., et al.
Publicado: (2020)

Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review
por: Indini, Alice, et al.
Publicado: (2021)

The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report
por: Hardenberg, M.C., et al.
Publicado: (2022)

Tumour travel tours – Why circulating cancer cells value company
por: Häfner, Sophia Julia
Publicado: (2020)

The Potential of Circulating Cell-Free DNA Methylation as an Epilepsy Biomarker
por: Martins-Ferreira, Ricardo, et al.
Publicado: (2022)

'Tumour volume' as a predictor of survival after resection of non-small-cell lung cancer (NSCLC)
por: Jefferson, M. F., et al.
Publicado: (1996)

Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC)
por: Sherwood, James L., et al.
Publicado: (2016)

Estimation of cell-free circulating EGFR mutation concentration predicts outcomes in NSCLC patients treated with EGFR-TKIs
por: Zhu, Yan-juan, et al.
Publicado: (2017)

COPD: understanding patients’ adherence to inhaled medications
por: Duarte-de-Araújo, António, et al.
Publicado: (2018)

Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation
por: Skvortsova, T E, et al.
Publicado: (2006)

Diagnostic and Prognostic Value of Circulating Cell-Free DNA for Cholangiocarcinoma
por: Wintachai, Preawwalee, et al.
Publicado: (2021)

Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA
por: Gremel, G., et al.
Publicado: (2016)

Impact of label-free technologies in head and neck cancer circulating tumour cells
por: Kulasinghe, Arutha, et al.
Publicado: (2016)

Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC)
por: Assi, Hazem I., et al.
Publicado: (2023)

Genetic profiling of tumours using both circulating free DNA and circulating tumour cells isolated from the same preserved whole blood sample
por: Rothwell, Dominic G., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_cfnusvnn5h7tthvov39a7v93q3